Want to see SE:ERMA full AI Analyst Report?
Enorama Pharma AB (ERMA) Stock Price & Analysis
ERMA Stock Chart & Stats
- Day’s Range
- SEK 0.76 - SEK 0.88
- 52-Week Range
- SEK 0.21 - SEK 2.86
- Previous Close
- SEK 0.83
- Volume
- N/A
- Average Volume (3M)
- 118.95K
- Market Cap
- SEK 62.21M
- Enterprise Value
- SEK 18.04M
- Total Cash (Recent Filing)
- SEK 2.10M
- Total Debt (Recent Filing)
- SEK 0
- Price to Earnings (P/E)
- ―
- Beta
- 1.01
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Effectively zero debt limits interest obligations and reduces refinancing pressure, giving the company a cleaner capital structure than a highly leveraged peer. This provides some flexibility to address operating challenges, although it does not remove the need to restore profitability and cash generation.
Proprietary NRT Platform
A focus on proprietary formulation and delivery technologies can support differentiated oral nicotine replacement products and more consumer-friendly cessation formats. If successfully commercialized, this platform orientation could improve product positioning and create a basis for repeatable growth beyond a single offering.
Improving Cash Flow Trend
The improvement in TTM free cash flow versus 2025 indicates some progress in cash consumption, even though the business remains materially cash-flow negative. Continued improvement would be important because it could gradually reduce external funding needs and support greater financial resilience.
Bears Say
Persistent Unprofitability
Recurring operating and net losses show that the current business model has not yet achieved sustainable profitability. Deeply negative margins leave limited evidence of operating leverage and increase the importance of future sales growth, cost control, and successful commercialization to establish durable earnings.
Sharp Revenue Contraction
A substantial TTM revenue decline weakens evidence of consistent product demand and reduces the scale available to absorb the company’s cost base. The reversal after stronger 2024 revenue suggests that growth has not yet become durable, increasing uncertainty around the path to commercial scale.
Negative Equity And Cash Burn
Negative equity combined with ongoing operating and free-cash-flow deficits indicates accumulated losses and continuing cash consumption. This weakens financial flexibility and may require external funding to sustain operations, making the company more vulnerable if commercialization or revenue recovery takes longer than expected.
ERMA FAQ
What was Enorama Pharma AB’s price range in the past 12 months?
What is Enorama Pharma AB’s market cap?
When is Enorama Pharma AB’s upcoming earnings report date?
How were Enorama Pharma AB’s earnings last quarter?
Is Enorama Pharma AB overvalued?
Does Enorama Pharma AB pay dividends?
What is Enorama Pharma AB’s EPS estimate?
How many shares outstanding does Enorama Pharma AB have?
What happened to Enorama Pharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Enorama Pharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Bengt Jönsson
- Employees
- 4
- Website
- www.enorama.se
- Address
- Strandvägen 7A, Stockholm, AB, 114 51, SE
Enorama Pharma AB (ERMA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 8 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 5 | 0 | 7 |
